PAR · SAN.PA
Sanofi
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
Loading market information…
PAR · NANO.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:37 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Nanobiotix S.A.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nanobiotix S.A.’s next earnings report is currently expected on Apr 27, 2027, with estimated earnings per share of €0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nanobiotix S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | May 22, 2024 | -€0.29+61.33% vs estimate | €32.90M |
|---|
| Q2 2023 | Nov 14, 2023 | -€0.460.0% vs estimate | €9.30M0.0% vs estimate |
|---|
| Q4 2022 | May 17, 2023 | -€0.29+61.33% vs estimate | €32.90M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
€178.20+€0.50 (+0.28%)
EssilorLuxottica S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.97% below the high.
€81.10+€0.35 (+0.43%)
Abivax S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.65% below the high.
€0.51+€0.09 (+22.01%)
Valerio Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.96% below the high.
€0.72-€0.01 (-1.63%)
Transgene S.A.’s quoted price sits in the lower half of its reported 52-week range, 51.8% below the high.
€1.29+€0.01 (+0.63%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.81% below the high.
€1.10-€0.03 (-2.3%)
Cellectis S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.8% below the high.
€1.07+€0.03 (+2.69%)
MaaT Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 87.59% below the high.
